Home > General Cardiology > Statins, liver enzyme monitoring, diabetes and cognitive side effects

Statins, liver enzyme monitoring, diabetes and cognitive side effects

The US Food and Drug Administration has issued a Drug Safety Communication regarding statin labelling.

This is instructive reading.

The key issues

  • Liver enzyme monitoring:  no longer routinely required.. Serious hepatic injury is rare and idiosyncratic. Monitoring does not appear effective in detecting this. Testing should be done on clinical grounds. e.g. symptoms, jaundice
  • Diabetes: recent trials and meta-analsys suggest:
    • small increased risk of new diabetes
    • increase in glycosylated Hb
  • Cognitive side effects:
    • recognised in post-marketing surveillance
    • limited data
    • “Data from the observational studies and clinical trials did not suggest that cognitive changes associated with statin use are common or lead to clinically significant cognitive decline.”

The statement is referenced.

Advertisements
  1. No comments yet.
  1. No trackbacks yet.

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

%d bloggers like this: